Centessa Stock Surges On Positive Data From Hemophilia Candidate

Centessa Pharmaceuticals plc CNTA has announced positive topline results from the Phase 2a part of AP-0101, the six-month repeat dose portion of the study evaluating SerpinPC in severe hemophilia A and B patients.
SerpinPC was well-tolerated. As previously disclosed, one subject with a history of skin disorder discontinued treatment on SerpinPC due to an injection site reaction.
No other SerpinPC-related adverse events have been recorded. In the highest dose cohort, SerpinPC reduced the self-reported all bleeds annualized bleeding rates (ABR ) by 88% during the last 12 weeks of treatment as compared to the all bleeds ABR measured during the pre-exposure observation period.
Five out of eight subjects had zero or one bleed in the highest dose cohort during the 12-week pre-specified primary assessment period.
Self-reported spontaneous joint bleeds ABR was reduced by 94% in the highest dose cohort.
All 22 patients who completed the Phase 2a portion of the study have elected to enroll in the 48-week open-label extension portion of the study.
A single flat 60 mg subcutaneous dose of SerpinPC will be administered every four weeks over 48 weeks.
Centessa expects to report results from the OLE portion in 2H of 2022.
Price Action: CNTA stock is up 19.9% at $25.25 during the market session on the last check Thursday.